We share a common purpose to generate attractive returns for investors by delivering significant and positive change in health.
“We see the opportunity to unlock enormous value for investors, health systems, and patients by focusing on the greatest burdens of global disease. With a remarkable team of highly successful individuals, we expect to generate returns through insightful selection of technology and unprecedented efficiency of development and commercialization. We believe that we can unlock as much value in prevalent disease in the next twenty years as we have seen industry unlock in oncology and rare diseases in the past twenty.”
– Clive Meanwell,
Chairman, Managing Partner
